
CGIX
Healthcare · Biotechnology · $48.7M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2019
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 31, 2020 | Time not confirmed | — | -1.05 | — |
| Sep 30, 2020 | Time not confirmed | — | -0.58 | — |
| Jun 30, 2020 | Time not confirmed | — | -0.82 | — |
| Mar 31, 2020 | Time not confirmed | — | -0.56 | — |
| Dec 31, 2019 | Time not confirmed | — | 0.04 | — |
| Sep 30, 2019 | Time not confirmed | — | -2.38 | — |
| Jun 30, 2019 | Time not confirmed | -4.80 | -0.24 | +95.0% |
| Mar 31, 2019 | Time not confirmed | -4.80 | -1.06 | +77.8% |
| Nov 19, 2018 | After the close | -5.10 | -9.30 | -82.4% |
| Aug 14, 2018 | After the close | -4.65 | -3.90 | +16.1% |
| May 15, 2018 | After the close | -3.90 | -4.80 | -23.1% |
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests,…